Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 32 words
    • Site contacts updated at 2 of 2 sites
    • Study description expanded, about 2 words
  2. Primary completion date: May 1, 2028 to Sep 1, 2028
    • Study completion date: Jan 1, 2029 to Mar 1, 2029
    v6
  3. Site contacts updated at 2 of 2 sitesv5
  4. Primary endpoints revised (2)
    • Eligibility criteria expanded, about 23 words
    v4
  5. Start date changed from estimate of Mar 25, 2025 to Apr 11, 2025v3
  6. Start date: Jan 2025 to Mar 25, 2025
    • Primary completion date: May 2028 to May 1, 2028
    • Study completion date: Jan 2029 to Jan 1, 2029
    • Site contacts updated at 2 of 2 sites
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Marzieh Salehi
1 trial monitored
See all monitored trials
Diabetes
5,141 trials monitored
See 246 trials at risk
Type 2 Diabetes
2,257 trials monitored
See 120 trials at risk
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Trial Details
NCT Number NCT06706284
Lead Sponsor Marzieh Salehi
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Spinal Cord Injuries, Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2, Spinal Cord Injuries
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov